Prediction of long-term outcome after acute myocardial infarction using circulating miR-145

References

• Writing Group Members, Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Roger VL, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J. Heart disease and stroke statistics – 2010 update: a report from the American Heart Association. Circulation 2010;121:e46–215.
   PubMed Web of Science ®Google Scholar
• Shafazand M, Rosengren A, Lappas G, Swedberg K, Schaufelberger M. Decreasing trends in the incidence of heart failure after acute myocardial infarction from 1993–2004: a study of 175,216 patients with a first acute myocardial infarction in Sweden. Eur J Heart Fail 2011;13:135–41.
   PubMedGoogle Scholar
• Kaul P, Ezekowitz JA, Armstrong PW, Leung BK, Savu A, Welsh RC, Quan H, Knudtson ML, McAlister FA. Incidence of heart failure and mortality after acute coronary syndromes. Am Heart J 2013;165:379–85.
   PubMedGoogle Scholar
• Grande P, Christiansen C, Pedersen A. Influence of acute myocardial infarct size on acute and one-year mortality. Eur Heart J 1983;4:20–5.
   PubMedGoogle Scholar
• Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, Blumenthal RS, Lima JA. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998;97:765–72.
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Kambara H, Fudo T, Tamaki S, Nohara R, Takatsu Y, Hattori R, Tokunaga S, Kawai C. Early estimation of acute myocardial infarct size soon after coronary reperfusion using emission computed tomography with technetium-99m pyrophosphate. Am J Cardiol 1987;60:952–7.
   PubMedGoogle Scholar
• Mahaffey KW, Roe MT, Kilaru R, Alexander JH, Van de Werf F, Califf RM, Simoons ML, Topol EJ, Harrington RA. Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non- ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials. Eur Heart J 2007;28:425–32.
   PubMedGoogle Scholar
• Lopes RD, Lokhnygina Y, Hasselblad V, Newby KL, Yow E, Granger CB, Armstrong PW, Hochman JS, Mills JS, Ruzyllo W, Mahaffey KW. Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy. Trials 2013;14:123.
   PubMed Web of Science ®Google Scholar
• Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120:15–20.
   PubMed Web of Science ®Google Scholar
• Kumarswamy R, Volkmann I, Thum T. Regulation and function of miRNA-21 in health and disease. RNA Biol 2011;8: 706–13.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Liu X, Zhang S, Lin Y, Yang J, Zhang C. MicroRNA-21 protects against the H(2)O(2)-induced injury on cardiac myocytes via its target gene PDCD4. J Mol Cell Cardiol 2009;47:5–14.
   PubMed Web of Science ®Google Scholar
• He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM. A microRNA polycistron as a potential human oncogene. Nature 2005;435:828–33.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Zhang C. MicroRNA-21 in cardiovascular disease. J Cardiovasc Transl Res 2010;3:251–5.
   PubMed Web of Science ®Google Scholar
• Urbich C, Kuehbacher A, Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res 2008;79:581–8.
   PubMed Web of Science ®Google Scholar
• Small EM, Frost RJ, Olson EN. MicroRNAs add a new dimension to cardiovascular disease. Circulation 2010; 121:1022–32.
   PubMed Web of Science ®Google Scholar
• Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, Weber M, Hamm CW, Röxe T, Müller-Ardogan M, Bonauer A, Zeiher AM, Dimmeler S. Circulating microRNAs in patients with coronary artery disease. Circ Res 2010;107:677–84.
   PubMed Web of Science ®Google Scholar
• Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, Seto AG, Lynch JM, Stack C, Latimer PA, Olson EN, van Rooij E. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 2011;124:1537–47.
   PubMed Web of Science ®Google Scholar
• Wang M, Li W, Chang GQ, Ye CS, Ou JS, Li XX, Liu Y, Cheang TY, Huang XL, Wang SM. MicroRNA-21 regulates vascular smooth muscle cell function via targeting tropomyosin 1 in arteriosclerosis obliterans of lower extremities. Arterioscler Thromb Vasc Biol 2011;31:2044–53.
   PubMedGoogle Scholar
• Meder B, Keller A, Vogel B, Haas J, Sedaghat-Hamedani F, Kayvanpour E, Just S, Borries A, Rudloff J, Leidinger P, Meese E, Katus HA, Rottbauer W. MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Res Cardiol 2011;106:13–23.
   PubMed Web of Science ®Google Scholar
• Oerlemans MI, Mosterd A, Dekker MS, de Vrey EA, van Mil A, Pasterkamp G, Doevendans PA, Hoes AW, Sluijter JP. Early assessment of acute coronary syndromes in the emergency department: the potential diagnostic value of circulating microRNAs. EMBO Mol Med 2012;4: 1176–85.
   PubMed Web of Science ®Google Scholar
• Bostjancic E, Zidar N, Glavac D. MicroRNA microarray expression profiling in human myocardial infarction. Dis Markers 2009;27:255–68.
   PubMed Web of Science ®Google Scholar
• Goren Y, Kushnir M, Zafrir B, Tabak S, Lewis BS, Amir O. Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail 2012;14:147–54.
   PubMed Web of Science ®Google Scholar
• Seto AG, van Rooij E. Circulating microRNAs to identify human heart failure. Eur J Heart Fail 2012;14:118–9.
   PubMedGoogle Scholar
• Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DS. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem 2011;57:84–91.
   PubMed Web of Science ®Google Scholar
• Rangrez AY, Massy ZA, Metzinger-Le Meuth V, Metzinger L. miR-143 and miR-145: molecular keys to switch the phenotype of vascular smooth muscle cells. Circ Cardiovasc Genet 2011;4:197–205.
   PubMed Web of Science ®Google Scholar
• Mayorga ME, Penn MS. miR-145 is differentially regulated by TGF-β1 and ischaemia and targets Disabled-2 expression and wnt/β-catenin activity. J Cell Mol Med 2012;16:1106–13.
   PubMedGoogle Scholar
• Engelhardt S, Leierseder S. Coinciding functions for miR-145 in vascular smooth muscle and cardiac fibroblasts. J Mol Cell Cardiol 2013;65:105–7.
   PubMedGoogle Scholar
• Xin M, Small EM, Sutherland LB, Qi X, McAnally J, Plato CF, Richardson JA, Bassel-Duby R, Olson EN. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev 2009;23:2166–78.
   PubMed Web of Science ®Google Scholar
• Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, Lee TH, Miano JM, Ivey KN, Srivastava D. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2009;460:705–10.
   PubMed Web of Science ®Google Scholar
• Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513–8.
   PubMed Web of Science ®Google Scholar